Sustained Pain Relief in Knee Osteoarthritis: New corticosteroid a Promising Prospect
Knee osteoarthritis (OA) poses challenges with limited long-term pain relief options. TLC599, a liposomal formulation of dexamethasone sodium phosphate, has emerged as a potential treatment offering prolonged relief. A Phase 3 study aimed to corroborate earlier phase 2 findings and assess the efficacy of repeated injections over a year. This study was published in the American College Of Rheumatology journal by George Spencer- Green and colleagues.
Key Findings
- Initial Injection Benefits:
TLC599 demonstrated superior efficacy over placebo for WOMAC pain and average daily pain (ADP) at Week 12 (p< 0.05).
ADP reduction with TLC599 was significantly better than DSP (p< 0.05) at Week 12, highlighting its efficacy compared to traditional corticosteroids.
- Repeated Injection Impact:
Patients receiving TLC599 for a second injection at Week 24 experienced sustained pain relief through Week 52.
Numerically superior ADP reduction with TLC599 compared to placebo persisted till Week 52, with statistical significance maintained through Week 34.
- Safety Profile:
TLC599 demonstrated a well-tolerated safety profile, with adverse events comparable across treatment groups.
Transient reduction in morning serum cortisol levels returned to normalcy within weeks, with no signs of adrenal insufficiency observed.
The study reinforces TLC599's efficacy in offering prolonged pain relief for knee OA. Its sustained benefits post-repeated injections till Week 52 mark a promising avenue for managing knee OA pain effectively. This suggests TLC599 as a prospective alternative for sustained relief in knee OA management.
Reference:
A phase 3 study of repeat injection of TLC599 in osteoarthritis of the knee: Benefits to 52 weeks. (2023, October 17). ACR Meeting Abstracts. https://acrabstracts.org/abstract/a-phase-3-study-of-repeat-injection-of-tlc599-in-osteoarthritis-of-the-knee-benefits-to-52-weeks/
